Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1001861

Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study


Papić, Neven; Budimir, Jelena; Kurelac, Ivan; Dušek, Davorka; Jugović, Davor; Krajcar, Nina; Vince, Adriana
Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study // Acta Clinica Croatica, 57 (2018), 1; 61-70 doi:10.20471/acc.2018.57.01.07 (recenziran, članak, znanstveni)


CROSBI ID: 1001861 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study

Autori
Papić, Neven ; Budimir, Jelena ; Kurelac, Ivan ; Dušek, Davorka ; Jugović, Davor ; Krajcar, Nina ; Vince, Adriana

Izvornik
Acta Clinica Croatica (0353-9466) 57 (2018), 1; 61-70

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
aged ; antiviral agents ; end stage liver disease ; hepatitis C – prognosis ; hepatitis C, chronic – treatment ; immunotherapy ; pegylated interferon alpha

Sažetak
The prevalence of chronic hepatitis C increases in elderly patients. The aims of this study were to identify the factors associated with hepatocellular carcinoma (HCC) and end- stage liver disease development and to evaluate the efficacy and safety of pegylated interferon (PEG- IFNα) plus ribavirin (RBV) therapy in elderly patients. A retrospective cohort study included all consecutive pa-tients with hepatitis C virus (HCV) infection treated with PEG- IFNα+RBV between 2003 and 2013. Elderly patients had a higher frequency of poor prognostic factors including genotype 1 infec-tion, high fibrosis, and high fibrosis index based on four factors (FIB-4) score. The sustained virologic response (SVR) rate for genotype 1 was significantly lower (35.8% vs. 57.1%), while the frequency of PEG-IFNα (27.2% vs. 7.8%), RBV dose reduction (19.6% vs. 9.7%) and treatment discontinuation (13.0% vs. 4.1%) was significantly higher in elderly patients. However, age was not associated with SVR in multivariate analysis, and comparable SVR rates were achieved when adjusted for fibrosis score (Ishak ≤3: 66.7% vs. 69.8%). During the follow-up, HCC was diagnosed in 18 elderly patients (3 SVR+, 4 SVR- and 9 untreated patients). In conclusion, selected elderly patients can achieve comparable SVR rates as younger patients, but with a higher rate of side effects. Since complications of HCV infection occur more frequently in elderly patients, they should be given priority for antiviral therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
Klinika za infektivne bolesti "Dr Fran Mihaljević"

Poveznice na cjeloviti tekst rada:

doi hrcak.srce.hr

Citiraj ovu publikaciju:

Papić, Neven; Budimir, Jelena; Kurelac, Ivan; Dušek, Davorka; Jugović, Davor; Krajcar, Nina; Vince, Adriana
Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study // Acta Clinica Croatica, 57 (2018), 1; 61-70 doi:10.20471/acc.2018.57.01.07 (recenziran, članak, znanstveni)
Papić, N., Budimir, J., Kurelac, I., Dušek, D., Jugović, D., Krajcar, N. & Vince, A. (2018) Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Acta Clinica Croatica, 57 (1), 61-70 doi:10.20471/acc.2018.57.01.07.
@article{article, author = {Papi\'{c}, Neven and Budimir, Jelena and Kurelac, Ivan and Du\v{s}ek, Davorka and Jugovi\'{c}, Davor and Krajcar, Nina and Vince, Adriana}, year = {2018}, pages = {61-70}, DOI = {10.20471/acc.2018.57.01.07}, keywords = {aged, antiviral agents, end stage liver disease, hepatitis C – prognosis, hepatitis C, chronic – treatment, immunotherapy, pegylated interferon alpha}, journal = {Acta Clinica Croatica}, doi = {10.20471/acc.2018.57.01.07}, volume = {57}, number = {1}, issn = {0353-9466}, title = {Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study}, keyword = {aged, antiviral agents, end stage liver disease, hepatitis C – prognosis, hepatitis C, chronic – treatment, immunotherapy, pegylated interferon alpha} }
@article{article, author = {Papi\'{c}, Neven and Budimir, Jelena and Kurelac, Ivan and Du\v{s}ek, Davorka and Jugovi\'{c}, Davor and Krajcar, Nina and Vince, Adriana}, year = {2018}, pages = {61-70}, DOI = {10.20471/acc.2018.57.01.07}, keywords = {aged, antiviral agents, end stage liver disease, hepatitis C – prognosis, hepatitis C, chronic – treatment, immunotherapy, pegylated interferon alpha}, journal = {Acta Clinica Croatica}, doi = {10.20471/acc.2018.57.01.07}, volume = {57}, number = {1}, issn = {0353-9466}, title = {Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study}, keyword = {aged, antiviral agents, end stage liver disease, hepatitis C – prognosis, hepatitis C, chronic – treatment, immunotherapy, pegylated interferon alpha} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font